Point-of-care testing and treatment of sexually transmitted and genital infections to improve birth outcomes in high-burden, low-resource settings (WANTAIM): a pragmatic cluster randomised crossover trial in Papua New Guinea.


Journal

The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665

Informations de publication

Date de publication:
Apr 2024
Historique:
received: 19 11 2023
revised: 13 12 2023
accepted: 02 01 2024
medline: 18 3 2024
pubmed: 15 3 2024
entrez: 14 3 2024
Statut: ppublish

Résumé

Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and bacterial vaginosis have been associated with adverse maternal and perinatal outcomes, but there is conflicting evidence on the benefits of antenatal screening and treatment for these conditions. We aimed to determine the effect of antenatal point-of-care testing and immediate treatment of C trachomatis, N gonorrhoeae, T vaginalis, and bacterial vaginosis on preterm birth, low birthweight, and other adverse maternal and perinatal outcomes compared with current standard of care, which included symptom-based treatment without laboratory confirmation. In this pragmatic cluster randomised crossover trial, we enrolled women (aged ≥16 years) attending an antenatal clinic at 26 weeks' gestation or earlier (confirmed by obstetric ultrasound), living within approximately 1 h drive of a study clinic, and able to provide reliable contact details at ten primary health facilities and their catchment communities (clusters) in Papua New Guinea. Clusters were randomly allocated 1:1 to receive either the intervention or control (standard care) in the first phase of the trial. Following an interval (washout period) of 2-3 months at the end of the first phase, each cluster crossed over to the other group. Randomisation was stratified by province. Individual participants were informed about trial group allocation only after completing informed consent procedures. The primary outcome was a composite of preterm birth (livebirth before 37 weeks' gestation), low birthweight (<2500 g), or both, analysed according to the intention-to-treat population. This study is registered with ISRCTN Registry, ISRCTN37134032, and is completed. Between July 26, 2017, and Aug 30, 2021, 4526 women were enrolled (2210 [63·3%] of 3492 women in the intervention group and 2316 [62·8%] of 3687 in the control group). Primary outcome data were available for 4297 (94·9%) newborn babies of 4526 women. The proportion of preterm birth, low birthweight, or both, in the intervention group, expressed as the mean of crude proportions across clusters, was 18·8% (SD 4·7%) compared with 17·8% in the control group (risk ratio [RR] 1·06, 95% CI 0·78-1·42; p=0·67). There were 1052 serious adverse events reported (566 in the intervention group and 486 in the control group) among 929 trial participants, and no differences by trial group. Point-of-care testing and treatment of C trachomatis, N gonorrhoeae, T vaginalis, and bacterial vaginosis did not reduce preterm birth or low birthweight compared with standard care. Within the subgroup of women with N gonorrhoeae, there was a substantial reduction in the primary outcome. UK Department of Health and Social Care; UK Foreign, Commonwealth and Development Office; UK Medical Research Council; the Wellcome Trust; the Australian National Health and Medical Research Council; and Swiss National Science Foundation.

Sections du résumé

BACKGROUND BACKGROUND
Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and bacterial vaginosis have been associated with adverse maternal and perinatal outcomes, but there is conflicting evidence on the benefits of antenatal screening and treatment for these conditions. We aimed to determine the effect of antenatal point-of-care testing and immediate treatment of C trachomatis, N gonorrhoeae, T vaginalis, and bacterial vaginosis on preterm birth, low birthweight, and other adverse maternal and perinatal outcomes compared with current standard of care, which included symptom-based treatment without laboratory confirmation.
METHODS METHODS
In this pragmatic cluster randomised crossover trial, we enrolled women (aged ≥16 years) attending an antenatal clinic at 26 weeks' gestation or earlier (confirmed by obstetric ultrasound), living within approximately 1 h drive of a study clinic, and able to provide reliable contact details at ten primary health facilities and their catchment communities (clusters) in Papua New Guinea. Clusters were randomly allocated 1:1 to receive either the intervention or control (standard care) in the first phase of the trial. Following an interval (washout period) of 2-3 months at the end of the first phase, each cluster crossed over to the other group. Randomisation was stratified by province. Individual participants were informed about trial group allocation only after completing informed consent procedures. The primary outcome was a composite of preterm birth (livebirth before 37 weeks' gestation), low birthweight (<2500 g), or both, analysed according to the intention-to-treat population. This study is registered with ISRCTN Registry, ISRCTN37134032, and is completed.
FINDINGS RESULTS
Between July 26, 2017, and Aug 30, 2021, 4526 women were enrolled (2210 [63·3%] of 3492 women in the intervention group and 2316 [62·8%] of 3687 in the control group). Primary outcome data were available for 4297 (94·9%) newborn babies of 4526 women. The proportion of preterm birth, low birthweight, or both, in the intervention group, expressed as the mean of crude proportions across clusters, was 18·8% (SD 4·7%) compared with 17·8% in the control group (risk ratio [RR] 1·06, 95% CI 0·78-1·42; p=0·67). There were 1052 serious adverse events reported (566 in the intervention group and 486 in the control group) among 929 trial participants, and no differences by trial group.
INTERPRETATION CONCLUSIONS
Point-of-care testing and treatment of C trachomatis, N gonorrhoeae, T vaginalis, and bacterial vaginosis did not reduce preterm birth or low birthweight compared with standard care. Within the subgroup of women with N gonorrhoeae, there was a substantial reduction in the primary outcome.
FUNDING BACKGROUND
UK Department of Health and Social Care; UK Foreign, Commonwealth and Development Office; UK Medical Research Council; the Wellcome Trust; the Australian National Health and Medical Research Council; and Swiss National Science Foundation.

Identifiants

pubmed: 38485431
pii: S2214-109X(24)00004-4
doi: 10.1016/S2214-109X(24)00004-4
pii:
doi:

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e641-e651

Investigateurs

Michaela A Riddell (MA)
Lisa M Vallely (LM)
Alice Mengi (A)
Steven G Badman (SG)
Nicola Low (N)
Handan Wand (H)
John W Bolnga (JW)
Delly Babona (D)
Glen D L Mola (GDL)
Virginia Wiseman (V)
Angela Kelly-Hanku (A)
Caroline S E Homer (CSE)
Christopher Morgan (C)
Stanley Luchters (S)
David M Whiley (DM)
Leanne J Robinson (LJ)
Lucy Au (L)
Irene Pukai-Gani (I)
Moses Laman (M)
Grace Kariwiga (G)
Pamela J Toliman (PJ)
Neha Batura (N)
Sepehr N Tabrizi (SN)
Stephen J Rogerson (SJ)
Suzanne M Garland (SM)
Rebecca J Guy (RJ)
Rosanna W Peeling (RW)
William S Pomat (WS)
John M Kaldor (JM)
Andrew J B Vallely (AJB)

Informations de copyright

Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The Papua New Guinea Institute of Medical Research (MAR, LMV, AM, LJR, AK-H, JWB, IP-G, ML, LA, PJT, WSP, and AJBV) and the Kirby Institute at the University of New South Wales (MAR, LMV, SGB, HW, AK-H, VW, RJG, JMK, and AJBV) have received subsidised test kits for research from Cepheid (Sunnyvale, CA, USA). All other authors declare no competing interests. All authors declare that neither they or their institutions have received direct funding from industry for this or any other research project.

Auteurs

Michaela A Riddell (MA)

Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea; The Kirby Institute, University of New South Wales Sydney, Kensington, NSW, Australia.

Lisa M Vallely (LM)

Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea; The Kirby Institute, University of New South Wales Sydney, Kensington, NSW, Australia.

Alice Mengi (A)

Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.

Steven G Badman (SG)

The Kirby Institute, University of New South Wales Sydney, Kensington, NSW, Australia.

Nicola Low (N)

Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.

Handan Wand (H)

The Kirby Institute, University of New South Wales Sydney, Kensington, NSW, Australia.

John W Bolnga (JW)

Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea; Modilon General Hospital, Madang, Papua New Guinea.

Delly Babona (D)

St Mary's Hospital Vunapope, Kokopo, Papua New Guinea.

Glen D L Mola (GDL)

School of Medicine and Health Sciences, University of Papua New Guinea, National Capital District, Papua New Guinea.

Virginia Wiseman (V)

The Kirby Institute, University of New South Wales Sydney, Kensington, NSW, Australia; London School of Hygiene & Tropical Medicine, London, UK.

Angela Kelly-Hanku (A)

Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea; The Kirby Institute, University of New South Wales Sydney, Kensington, NSW, Australia.

Caroline S E Homer (CSE)

Burnet Institute, Melbourne, VIC, Australia.

Christopher Morgan (C)

Burnet Institute, Melbourne, VIC, Australia; Jhpiego the Johns Hopkins University affiliate, Baltimore, MD, USA.

Stanley Luchters (S)

Centre for Sexual Health and HIV/AIDS Research, Harare, Zimbabwe; Liverpool School of Tropical Medicine, Liverpool, UK.

David M Whiley (DM)

UQ Centre for Clinical Research, University of Queensland, Herston, QLD, Australia; Pathology Queensland Central Laboratory, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.

Leanne J Robinson (LJ)

Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea; Burnet Institute, Melbourne, VIC, Australia.

Lucy Au (L)

Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.

Irene Pukai-Gani (I)

Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.

Moses Laman (M)

Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.

Grace Kariwiga (G)

Alotau Provincial Hospital, Alotau, Milne Bay Province, Papua New Guinea.

Pamela J Toliman (PJ)

Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea; The Kirby Institute, University of New South Wales Sydney, Kensington, NSW, Australia.

Neha Batura (N)

University College London Institute for Global Health, London, UK.

Sepehr N Tabrizi (SN)

Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC, Australia; Centre for Women's Infectious Diseases Research, The Royal Women's Hospital Melbourne, VIC, Australia.

Stephen J Rogerson (SJ)

Department of Infectious Diseases, University of Melbourne, Melbourne, VIC, Australia; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.

Suzanne M Garland (SM)

Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC, Australia; Centre for Women's Infectious Diseases Research, The Royal Women's Hospital Melbourne, VIC, Australia.

Rebecca J Guy (RJ)

The Kirby Institute, University of New South Wales Sydney, Kensington, NSW, Australia.

Rosanna W Peeling (RW)

London School of Hygiene & Tropical Medicine, London, UK.

William S Pomat (WS)

Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea; The Kirby Institute, University of New South Wales Sydney, Kensington, NSW, Australia.

John M Kaldor (JM)

The Kirby Institute, University of New South Wales Sydney, Kensington, NSW, Australia.

Andrew J B Vallely (AJB)

Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea; The Kirby Institute, University of New South Wales Sydney, Kensington, NSW, Australia. Electronic address: avallely@kirby.unsw.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH